A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories

Breast Cancer Research and Treatment

Volumn 138, Issue 3, 2013, Pages 691-698

  Szekely, Borbala ^a   Iwamoto, Takayuki ^b   Szasz, A Marcell ^a   Qi, Yuan ^c   Matsuoka, Junji ^d   Symmans, W Fraser ^e   Tokes, Anna Maria ^a   Kulka, Janina ^a   Swanton, Charles ^f,g   Pusztai, Lajos ^h  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

^e UNIVERSITY OF TEXAS   (United States)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; FOXM1; Genomic grade index; Histological Grade; MKI67; TOP2A

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RISK; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOXM1 GENE; GENE; GENE EXPRESSION; GENETIC DATABASE; GENOMIC GRADE INDEX; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MKI67 GENE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; TOP2A GENE;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DATABASES, GENETIC; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; KI-67 ANTIGEN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL RATE; TAMOXIFEN;

EID: 84877833969     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2475-4     Document Type: Article

References (27)

1. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219
2. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
3. Simpson JF, Gray R, Dressler LG et al (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059-2069
4. Frierson HF, Wolber RA, Berean KW et al (1995) Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195-198
5. Dalton LW, Page DL, Dupont WD (1994) Histologic grading of breast carcinoma: a reproducibility study. Cancer 73:2765-2770
6. Robbins P, Pinder S, de Klerk N et al (1995) Histologic grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26:873-879
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262-272
8. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65
9. Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart M, Foekens JA, Durbecq V, Sotiriou C (2009) Improvement of the clinical applicability of the genomic grade index through a qrt-pcr test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 10:424. doi: 10.1186/1471-2164-10-424
10. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D (2008) A five-gene molecular grade index and hoxb13:Il17br are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14(9):2601-2608
11. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2010) Mib1/ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127(3):591-599. doi: 10.1007/s10549-010-1028-3
12. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440
13. Myatt SS, Lam EW (2007) The emerging roles of forkhead box (fox) proteins in cancer. Nat Rev Cancer 7(11):847-859
14. Wierstra I, Alves J (2007) Foxm1, a typical proliferation-associated transcription factor. Biol Chem 388(12):1257-1274
15. Duchrow M, Gerdes J, Schlüter C (1994) The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif 27:235-242
16. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8(12):1079-1087
17. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26(25):4063-4071
18. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405-5413
19. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transbig multicenter independent validation series. Clin Cancer Res 13(11):3207-3214
20. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25(10):1239-1246
21. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4273
22. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and erbb2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203-211
23. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van't Veer L et al (2008) Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9:394
24. Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826
26. Sotiriou C, Pusztai L (2009) Gene expression signatures in breast cancer. N Engl J Med 360(8):790-800
27. Szasz AM, Li Q, Eklund AC, Sztupinszki Z, Rowan A, Tokes AM, Szekely B, Kiss A, Szendroi M, Gyorffy B, Szallasi Z, Swanton C, Kulka J (2013) The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS One 8(2):e56707